Tesamorelin Research Peptide (GHRH Analog)
Lyophilized Format • ≥99% HPLC Purity • Ships in 1–2 Business Days • U.S. Warehouses
Tesamorelin (TH9507, CAS 218949-48-5) is a synthetic 44 amino acid analog of human Growth Hormone-Releasing Hormone (GHRH 1-44) with a trans-3-hexenoic acid modification at the N-terminus, developed by Theratechnologies Inc. in Montreal, Canada, supplied by Nextday Peptides in lyophilized format for laboratory and analytical research applications. The trans-3-hexenoyl N-terminal modification was engineered to enhance resistance to DPP-IV enzymatic degradation compared to native GHRH while maintaining full GHRH receptor agonist activity, making it one of the most stable synthetic GHRH analogs available for laboratory research. Each vial is independently verified to ≥99% HPLC purity with a Certificate of Analysis available on request. For scientific research use only.
Compound Specifications
| Compound Name | Tesamorelin / TH9507 / Trans-3-hexenoyl-GHRH(1-44) |
| Amino Acids | 44 |
| N-Terminal Modification | Trans-3-hexenoic acid group — DPP-IV resistance enhancement |
| Receptor Target | GHRH Receptor (GHRHR) on pituitary somatotrophs |
| Molecular Formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Molecular Weight | 5,135.9 g/mol |
| CAS Number | 218949-48-5 |
| Form | Lyophilized powder |
| Appearance | White to off-white powder |
| Purity | ≥99% (HPLC verified) |
| Storage | -20°C lyophilized; 2–8°C after reconstitution |
| Synonyms | TH9507, Egrifta sequence, Trans-3-hexenoyl-hGHRH(1-44)-NH₂ |
Why Research Laboratories Select Tesamorelin
Tesamorelin is one of the most studied GHRH analog peptides in current endocrine research literature — distinguished from shorter GHRH analogs like Sermorelin (29 AA) and CJC-1295 (29 AA) by its full 44 amino acid GHRH sequence combined with a unique N-terminal lipophilic modification that dramatically enhances DPP-IV resistance. This combination of full-length GHRH sequence and enhanced enzymatic stability makes it a valuable reference compound for laboratories studying GHRH receptor binding kinetics, pituitary somatotroph signaling, endocrine feedback loop dynamics, and comparative GHRH analog pharmacology.
- Full-length 44 amino acid GHRH analog — longest GHRH research peptide available compared to 29 AA analogs
- Trans-3-hexenoyl N-terminal modification — unique lipophilic group enhancing DPP-IV resistance beyond CJC-1295 and Sermorelin
- GHRH receptor full agonist — activates cAMP/PKA signaling cascade via pituitary somatotroph GHRHR
- Maintains pulsatile GH secretion patterns in experimental models — studied in endocrine feedback loop research
- FDA-approved pharmaceutical equivalent (Egrifta) — most extensive human clinical trial literature of any GHRH research analog
- Phase 3 human clinical trial data published — Falutz et al. (2007, 2008) in J Clin Endocrinol Metab and J Acquir Immune Defic Syndr
- Lyophilized format ensures stability and reproducibility across experimental runs
- Batch and lot identifiers on all labeling for full laboratory documentation compliance
Research Background
Tesamorelin was developed by Theratechnologies Inc. in Montreal as a stabilized GHRH analog. The trans-3-hexenoyl N-terminal modification was specifically engineered to overcome the rapid DPP-IV enzymatic degradation that limits native GHRH research utility. Falutz et al. (2007) published Phase 3 findings in the Journal of Clinical Endocrinology & Metabolism. A subsequent multicenter study was published in the Journal of Acquired Immune Deficiency Syndromes (2008). The pharmaceutical form, Egrifta (tesamorelin), received FDA approval in 2010 for HIV-associated lipodystrophy. Research-grade Tesamorelin supplied by Nextday Peptides is not equivalent to any approved pharmaceutical formulation. All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance.
Reference sources: Falutz et al. (2007) — Journal of Clinical Endocrinology & Metabolism | FDA — Egrifta Approval
⚠️ Regulatory Notice
Research-grade Tesamorelin supplied by Nextday Peptides is not equivalent to Egrifta (Tesamorelin, Theratechnologies Inc.) or any other approved pharmaceutical formulation. It is supplied strictly for controlled in-vitro laboratory research use only by qualified research professionals. It is not for human or veterinary use, is not a drug product, and must not be administered to humans or animals under any circumstances.
Shipping & Fulfillment
- Ships from U.S. warehouses — Florida, North Carolina, and California
- Overnight and 2-day shipping available at checkout
- Same-day processing on orders placed before 3:30 PM ET
- Discreet packaging with full tracking provided
- Bulk research orders welcome — contact us for volume pricing
Storage & Handling
- Store lyophilized peptide at -20°C away from light and moisture
- After reconstitution store at 2–8°C and use within 7 days
- Avoid repeated freeze-thaw cycles to maintain peptide integrity
- Handle using appropriate laboratory safety protocols
- Keep containers sealed when not in use
Frequently Asked Questions
What is Tesamorelin?
Tesamorelin (TH9507, CAS 218949-48-5) is a synthetic 44 amino acid GHRH analog with a trans-3-hexenoyl N-terminal modification that enhances DPP-IV resistance. Developed by Theratechnologies Inc. it is studied as a GHRH receptor agonist for investigating pituitary somatotroph signaling and endocrine pathway biology. Supplied strictly for scientific, analytical, and in-vitro laboratory research use only.
How does Tesamorelin differ from Sermorelin and CJC-1295?
Sermorelin and CJC-1295 are both 29 amino acid GHRH analogs. Tesamorelin is a full 44 amino acid GHRH analog — matching the complete endogenous GHRH(1-44) sequence. Its trans-3-hexenoyl N-terminal modification provides DPP-IV resistance through a different mechanism than the amino acid substitutions used in CJC-1295. The full-length sequence and unique N-terminal modification make Tesamorelin distinct from all shorter GHRH analogs in GHRH receptor binding studies.
What is the trans-3-hexenoyl modification?
The trans-3-hexenoyl group is a lipophilic fatty acid derivative attached to the N-terminal tyrosine of the GHRH sequence. This modification sterically protects the peptide bond from DPP-IV enzymatic cleavage — the primary route of GHRH degradation — significantly extending the compound’s stability in experimental systems compared to native GHRH or unmodified 29 amino acid analogs.
Is Tesamorelin FDA approved?
The pharmaceutical form of Tesamorelin (Egrifta, Theratechnologies Inc.) received FDA approval in November 2010 for HIV-associated lipodystrophy. Research-grade Tesamorelin supplied by Nextday Peptides is not equivalent to any approved drug product and is supplied for laboratory research use only — not for human administration.
What purity is your Tesamorelin?
Every batch is independently verified to ≥99% HPLC purity. A Certificate of Analysis is available for each lot.
How fast does Nextday Peptides ship?
We ship from U.S. warehouses in Florida, North Carolina, and California. Overnight and 2-day shipping options are available. Orders placed before 3:30 PM ET are processed same day.
Are bulk orders available?
Yes. We accommodate bulk research orders. Contact us directly for volume pricing and availability.
Is this product approved for medical use?
No. Research-grade Tesamorelin is not approved for human or veterinary use and is not equivalent to any approved drug product. It is for laboratory research use only and is not intended for diagnostic, therapeutic, or clinical applications.
What other compounds does Nextday Peptides carry?
We also carry Sermorelin, CJC-1295 No DAC, CJC-1295 with DAC, and Ipamorelin. View our full research compounds catalog.
For Research Use Only — Not for human or veterinary consumption • Not equivalent to any approved drug product • Supplied by Nextday Peptides for controlled in-vitro laboratory research use only
